Compounded vs FDA-approved semaglutide: what is actually different

TLDR. Compounded semaglutide is the same molecule as Wegovy and Ozempic but a different regulatory product. The FDA declared the semaglutide shortage resolved in February 2025. That weakened the legal basis for 503A compounded versions. Hims exited compounded for new patients in March 2026 as part of a Novo settlement. Mochi, Found, and Noom Med still dispense compounded with live regulatory exposure. Price gap is shrinking: compounded at $99 to $199/mo versus NovoCare Wegovy at $149/mo introductory and $499 maintenance. The molecule is identical; the manufacturing oversight is not.

For two years, compounded semaglutide was the cheap tier of the GLP-1 market. It was how Hims sold weight-loss treatment for $199/mo when Wegovy retailed at $1,300. It was how Mochi, Found and a dozen smaller telehealth programs built businesses around cash-pay patients priced out of the branded products.

That era is ending. Hims exited compounded for new patients on March 9, 2026. Ro never re-entered. Calibrate exited. WeightWatchers Clinic exited. Of the major programs, only Mochi, Found and Noom Med still actively dispense compounded GLP-1s and all three have live regulatory exposure.

So what is actually different between a compounded and an FDA-approved semaglutide? The molecule is the same. Almost everything around it is not: the regulation, the sourcing, the safety profile, and how long the supply will keep flowing. Those differences matter.

The molecule is identical. The drug is not.

Wegovy and Ozempic are the same active ingredient: semaglutide. The compounded versions Mochi, Found and Noom prescribe are also semaglutide. The molecule is identical at the chemistry level. A patient who takes 1mg of injectable semaglutide gets the same molecule whether it came in a Novo Nordisk pen or a 503A pharmacy vial.

What differs is everything around the molecule:

• Manufacturing oversight. Wegovy is produced under FDA Current Good Manufacturing Practices (cGMP) at facilities the FDA inspects. 503A compounded semaglutide is produced one prescription at a time at a pharmacy under state board of pharmacy oversight. The FDA does not inspect 503A pharmacies the same way.
• Identity and potency testing. Branded products undergo extensive batch testing. Compounded products undergo testing only to the extent the pharmacy chooses or the state requires. There have been documented cases of compounded GLP-1 vials testing at incorrect potency or containing related but distinct compounds.
• Sterility. Injectable medications must be sterile. Branded products are produced in large-scale aseptic facilities. Compounded products are sterilized at the pharmacy. In 2025, the FDA shut down a major compounding pharmacy after sterility failures linked to GLP-1 injection contamination.
• Regulatory legitimacy. The FDA temporarily allowed compounded GLP-1s during the 2023-2024 branded shortage. That window has now closed for semaglutide; the FDA declared the shortage resolved in October 2024. Compounded semaglutide is now an enforcement target, not a regulatory grey zone.

Why compounded was so much cheaper

The savings traced back to three structural facts.

1. No drug-development amortization. Novo Nordisk spent over a decade and a few billion dollars developing semaglutide. Wegovy's price reflects recovering that investment. A 503A pharmacy buys raw semaglutide API from a supplier and mixes it; there is no R&D recovery in the price.
2. No marketing or sales force. Branded GLP-1 prices reflect the cost of marketing to physicians, advertising to patients and maintaining a global sales infrastructure. Compounded GLP-1s reach patients through the prescribing telehealth program; there is no separate marketing layer.
3. No insurance overhead. Branded products go through complex pharmacy benefit management (PBM) systems with rebates, formulary negotiations and prior authorization workflows. Compounded products are usually cash-pay direct-to-patient; the PBM layer is absent.

The cost stack is genuinely different. The price difference was not arbitrage; it was structural.

Why the cheap tier is ending

In 2025-2026, three forces converged to close the compounded path:

• FDA shortage declaration. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in late 2024. Once a shortage is resolved, the legal basis for 503A compounded versions of those drugs is meaningfully weaker. Pharmacies can still compound under specific medical-necessity exceptions, but the broad commercial path is closed.
• Manufacturer litigation. Novo Nordisk and Eli Lilly have filed coordinated lawsuits against compounding pharmacies and the telehealth programs that distribute through them. The Hims-Novo settlement of March 2026 is the bellwether: Hims paid an undisclosed sum and exited compounded semaglutide for new patients, in exchange for an official Wegovy distribution partnership. Other programs face the same pattern.
• Pharmacy enforcement. The FDA has shut down multiple compounding pharmacies for sterility failures specific to GLP-1 production. Pharmacies that survive the enforcement wave have pulled back on volume. Mochi lost a partner pharmacy in 2025 to FDA enforcement; supply has been less consistent since.

The combined effect: even programs that still offer compounded GLP-1s are doing so under regulatory uncertainty, with shrinking supply and with the implicit knowledge that the path could close on short notice.

What this means for patients on compounded right now

If you are on a compounded GLP-1 today, here is where you stand.

One: your compounded GLP-1 is not unsafe. If your program is dispensing through a 503A pharmacy with a clean enforcement history, the medication is the same molecule as the branded product and there is no clinical reason to assume it works differently. The risks are real but they are tail risks: occasional batch issues, occasional supply interruptions, occasional regulatory shutdowns.

Two: the supply is not guaranteed to last. Patients on compounded should have a transition plan. Most programs will route compounded patients to branded products under insurance prior authorization if compounded supply is forced to halt. Prior auth takes 1-4 weeks. Plan for that.

Three: the savings are eroding. Branded direct-to-consumer pricing has dropped meaningfully, Wegovy now starts at $149/mo via NovoCare, Zepbound vials start at $299/mo via LillyDirect. The price gap between compounded ($99-$199 cash) and branded ($149-$399 cash) is not what it was in 2023.

How we score it

In our methodology, compounded availability scores well on the medication-options dimension (broad access, lower price ceiling) and poorly on the regulatory dimension (supply uncertainty, enforcement risk). Programs that offer both paths, Found, Noom Med, score higher on medication options than programs locked to one path or the other.

The tradeoff is real either way: pay more for branded regulatory clarity, or pay less for compounded and accept that the path may close. What does not hold up is the marketing line that the two are interchangeable. They are the same molecule. They are not the same product.

Frequently asked questions

Is compounded semaglutide the same drug as Wegovy?

The active molecule is identical: semaglutide. A patient taking 1 mg from a compounding pharmacy vial receives the same chemical as the Wegovy pen. What differs is the regulatory frame: Wegovy is produced under FDA cGMP at inspected facilities with batch testing, while 503A compounded semaglutide is mixed prescription by prescription at a pharmacy under state board oversight, with testing only as the pharmacy chooses.

Is compounded semaglutide safe?

Most 503A pharmacies with clean enforcement histories produce safe product. Tail risks are real: documented cases of incorrect potency, related-but-distinct compounds, and a 2025 FDA shutdown of a major compounding pharmacy after sterility failures linked to GLP-1 contamination. Ask any program whether they disclose pharmacy partner, batch testing protocols, and recent enforcement history.

Why was compounded semaglutide ever legal?

Federal law allows 503A pharmacies to compound a drug while the FDA-approved version is on the shortage list. Semaglutide was on the shortage list from 2022 to February 2025. Once the FDA declared the shortage resolved, the broad commercial path for compounded semaglutide closed; pharmacies can still compound under narrow medical-necessity exceptions, but the legal basis is meaningfully weaker.

What happens to my prescription if my compounded pharmacy gets shut down?

Most programs route compounded patients to branded products under insurance prior authorization if compounded supply is forced to halt. Prior authorization takes 1 to 4 weeks. Build a transition plan: know whether your insurance covers Wegovy or Zepbound, ask your program what their backup pharmacy is, and keep a 30-day buffer in your refrigerator if you can.

Is compounded still cheaper than NovoCare or LillyDirect direct programs?

Less than it used to be. Wegovy through NovoCare now starts at $149/mo introductory and $299 to $499/mo maintenance. Zepbound vials through LillyDirect start at $299/mo. Compounded sits at $99 to $199/mo. The savings are real but the gap is roughly half what it was in 2023, and that gap closes further if the regulatory path narrows.

If you are on compounded semaglutide and want to know exactly which pharmacy is making it, and how to vet them, see which pharmacy compounds your GLP-1.